Eckardt, J.-N.; Stasik, S.; Kramer, M.; Röllig, C.; Krämer, A.; Scholl, S.; Hochhaus, A.; Crysandt, M.; Brümmendorf, T.H.; Naumann, R.;
et al. Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Cancers 2021, 13, 2095.
https://doi.org/10.3390/cancers13092095
AMA Style
Eckardt J-N, Stasik S, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R,
et al. Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Cancers. 2021; 13(9):2095.
https://doi.org/10.3390/cancers13092095
Chicago/Turabian Style
Eckardt, Jan-Niklas, Sebastian Stasik, Michael Kramer, Christoph Röllig, Alwin Krämer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. Brümmendorf, Ralph Naumann,
and et al. 2021. "Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia" Cancers 13, no. 9: 2095.
https://doi.org/10.3390/cancers13092095
APA Style
Eckardt, J.-N., Stasik, S., Kramer, M., Röllig, C., Krämer, A., Scholl, S., Hochhaus, A., Crysandt, M., Brümmendorf, T. H., Naumann, R., Steffen, B., Kunzmann, V., Einsele, H., Schaich, M., Burchert, A., Neubauer, A., Schäfer-Eckart, K., Schliemann, C., Krause, S. W.,
... Middeke, J. M.
(2021). Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Cancers, 13(9), 2095.
https://doi.org/10.3390/cancers13092095
